Track Immuneering Corporation Class A Common Stock — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Immuneering Corporation Class A Common Stock IMRX Open Immuneering Corporation Class A Common Stock in new tab

5.45 USD
EPS
-1.27
P/B
1.61
ROE
-43.12
Beta
0.43
Target Price
17.00 USD
Immuneering Corporation Class A Common Stock logo

Immuneering Corporation Class A Common Stock

🧾 Earnings Recap – Q3 2025

Immuneering Corporation delivered a compelling third quarter of 2025 highlighted by promising clinical results from its Phase 2a trial of atebimetinib in combination with FOLFIRINOX for pancreatic cancer patients.

  • Reported significant overall survival improvements in first-line pancreatic cancer patients treated with atebimetinib and FOLFIRINOX, strengthening development pipeline.
  • A case study showcased a 71-year-old patient achieving a 100% reduction in liver lesions after five months of treatment, indicating strong efficacy and safety profile.
  • Company plans to share substantial data updates in 2026, with potential presence at major medical meetings.
  • Ongoing trials aim to enhance treatment options for pancreatic cancer, which remains a significant area of unmet medical need.
📅
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateMay 4, 2026
EPS-1.27
Book Value3.38
Price to Book1.61
Debt/Equity1.75
% Insiders17.826%
Estimates
Forward P/E-4.03
Forward EPS-1.35
Target Mean Price17.00

DCF Valuation

Tweak assumptions to recompute fair value for Immuneering Corporation Class A Common Stock (IMRX)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Immuneering Corporation Class A Common Stock Logo Immuneering Corporation Class A Common Stock Analysis (IMRX)

United States Health Care Official Website Stock

Is Immuneering Corporation Class A Common Stock a good investment? Immuneering Corporation Class A Common Stock (IMRX) is currently trading at 5.45 USD. Market analysts have a consensus price target of 17.00 USD. This suggests a potential upside from current levels.

Earnings Schedule: Immuneering Corporation Class A Common Stock is expected to release its next earnings report on May 4, 2026. The market consensus estimate for Forward EPS is -1.35.

Investor FAQ

Does Immuneering Corporation Class A Common Stock pay a dividend?

No, it does not currently pay a dividend.

What asset class is Immuneering Corporation Class A Common Stock?

Immuneering Corporation Class A Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be May 4, 2026. The company currently has a trailing EPS of -1.27.

Company Profile

Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inhibitor discovery programs. The company has clinical supply agreements with Regeneron Pharmaceuticals to evaluate atebimetinib in combination with Libtayo in patients with unresectable or metastatic RAS-mutant non-small cell lung cancer; and with Eli Lilly and Company to evaluate atebimetinib in combination with olomorasib in patients with advanced or metastatic KRAS G12C-mutant non-small cell lung cancer. Immuneering Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Exchange Ticker
NMS (United States) IMRX

Dividends

Historical Split Corporate Actions

Trades
Trade History
No trades yet
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion